Bioamber (BIOA) Upgraded to Hold by ValuEngine

Bioamber (NYSE:BIOA) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

A number of other brokerages have also weighed in on BIOA. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Bioamber in a report on Wednesday, November 8th. Zacks Investment Research lowered shares of Bioamber from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Finally, Cowen reiterated a “hold” rating and issued a $1.00 price target on shares of Bioamber in a report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $6.50.

Shares of Bioamber (NYSE BIOA) traded down $0.03 on Wednesday, hitting $0.07. 12,990,000 shares of the company’s stock were exchanged, compared to its average volume of 2,860,000. The firm has a market cap of $2.17, a price-to-earnings ratio of -0.10 and a beta of 2.52. Bioamber has a 52 week low of $0.06 and a 52 week high of $3.74. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.75 and a current ratio of 1.08.

Several large investors have recently bought and sold shares of the stock. FMR LLC lifted its holdings in shares of Bioamber by 1.9% during the 2nd quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock valued at $3,495,000 after acquiring an additional 25,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Bioamber by 9.9% during the 2nd quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock valued at $780,000 after acquiring an additional 27,278 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Bioamber by 336.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock valued at $139,000 after acquiring an additional 41,701 shares in the last quarter. Finally, Robecosam AG lifted its holdings in shares of Bioamber by 82.9% during the 3rd quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock valued at $741,000 after acquiring an additional 670,000 shares in the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/02/14/bioamber-bioa-upgraded-to-hold-by-valuengine.html.

Bioamber Company Profile

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply